退热镇痛药使用与第二剂BNT162b2 mRNA疫苗接种后SARS-CoV-2抗体滴度的关联:一项观察性研究
本研究纳入日本东京某医疗研究机构1,498名已完成第二剂BNT162b2疫苗接种的员工,通过问卷获取预防性或治疗性使用退热镇痛药情况,并在接种后3个月定量检测抗SARS-CoV-2刺突蛋白IgG滴度。线性回归分析显示,治疗性使用退热镇痛药者IgG滴度高于未使用者(GMR=1.26,95%CI=1.17-1.34),调整症状后关联减弱但仍具统计学显著性(GMR=1.14,95%CI=1.06-1.23);预防性使用与抗体滴度无显著关联(GMR=0.96,95%CI=0.84-1.10)。结论认为未发现预防性或治疗性使用退热镇痛药抑制第二剂接种后的体液免疫应答。
要点
- 治疗性使用退热镇痛药者抗SARS-CoV-2刺突蛋白IgG几何平均滴度为6,147(95%CI=5,833-6,460),未使用者为4,895(95%CI=4,676-5,115)。
- 治疗性使用与较高抗体滴度相关(GMR=1.26,95%CI=1.17-1.34),调整症状后关联减弱但仍显著(GMR=1.14,95%CI=1.06-1.23)。
- 预防性使用退热镇痛药与抗体滴度无显著关联(GMR=0.96,95%CI=0.84-1.10)。
核心结论
- 未发现预防性或治疗性使用退热镇痛药抑制第二剂SARS-CoV-2疫苗接种后的体液免疫应答。
研究设计与样本
- 观察性研究,纳入日本东京某医疗研究机构1,498名已完成第二剂BNT162b2疫苗接种的员工。
- 接种后3个月定量检测抗SARS-CoV-2刺突蛋白IgG滴度,通过问卷获取预防性和治疗性退热镇痛药使用情况。
- 采用线性回归模型分析退热镇痛药使用与对数转换后的抗SARS-CoV-2刺突蛋白IgG滴度的关联,并基于模型参数估计几何平均滴度(GMT)及95%CI。
主要发现
- 治疗性使用退热镇痛药者IgG几何平均滴度为6,147(95%CI=5,833-6,460),未使用者为4,895(95%CI=4,676-5,115),GMR=1.26(95%CI=1.17-1.34)。
- 调整症状后,治疗性使用与抗体滴度的关联减弱但仍具统计学显著性(GMR=1.14,95%CI=1.06-1.23)。
- 预防性使用退热镇痛药者IgG几何平均滴度为5,245(95%CI=4,577-5,913),未使用者为5,452(95%CI=5,258-5,645),GMR=0.96(95%CI=0.84-1.10),无显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antipyretic analgesics are used to manage and control symptoms occurring after vaccination, but may hamper immunogenicity or vaccine efficacy. We examined the association between prophylactic or therapeutic use of antipyretic analgesics and SARS-CoV-2 antibody titers for vaccine recipients. Data were obtained from 1,498 staff members of a medical and research institution in Tokyo, Japan, who had received the second dose of the BNT162b2 vaccine. We quantitatively measured anti-SARS-CoV-2 spike protein IgG titers in the participants three months after vaccination. The prophylactic and therapeutic use of antipyretic analgesics was ascertained via a questionnaire. A linear regression model was used to examine the association between antipyretic analgesic use and log-transformed anti-SARS-CoV-2 spike protein IgG titers. Based on model parameters, we estimated geometric mean titers (GMT) and the corresponding 95 % confidence intervals (CI). The results showed that IgG titers in vaccine recipients who used antipyretic analgesics therapeutically was higher than the titers in those who did not (geometric mean ratio [GMR] = 1.26, 95 % CI = 1.17-1.34) with GMTs being 6,147 (95 % CI = 5,833-6,460) and 4,895 (95 % CI = 4,676-5,115) for those who used antipyretic analgesics therapeutically and those who did not, respectively. The association was attenuated, but remained statistically significant after adjusting for symptoms (GMR = 1.14, 95 % CI = 1.06-1.23). We did not find any evidence of significant association in relation to the prophylactic use of antipyretic analgesics (GMR = 0.96, 95 % CI = 0.84-1.10), with GMTs being 5,245 (95 % CI = 4,577-5,913) and 5,452 (95 % CI = 5,258-5,645) for those who used antipyretic analgesics prophylactically and those who did not, respectively. In conclusion, we did not find any evidence of suppression of the humoral response after the second dose of SARS-CoV-2 vaccination by prophylactic or therapeutic use of antipyretic analgesics.
引用
- Inoue Y, Li Y, Yamamoto S, et al. The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study. Vaccine. 2023. PMID: 37945490. doi:10.1016/j.vaccine.2023.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。